Literature DB >> 6644762

The association of the slow acetylator phenotype with bladder cancer.

D A Evans, L C Eze, E J Whibley.   

Abstract

There is an association between exposure to aromatic amines and the development of bladder cancer. Aromatic amines such as are known to occur in tobacco smoke are polymorphically acetylated. One hundred bladder cancer patients have been acetylator phenotyped. Only three of them were non-smokers at the time of diagnosis. This new series, together with four previous series (each with its own control), have been statistically analysed together. The results show a significant association between the slow acetylator phenotype and bladder cancer. The slow acetylator phenotype is associated about 39% more with bladder cancer than is the rapid acetylator phenotype. This association can be interpreted in one of two ways: (1) rapid acetylators may be protected against developing bladder cancer because they are better able to render amines non-carcinogenic by acetylation, or (2) slow acetylators have greater survival with bladder cancer than rapid acetylators. Further evidence will be required to differentiate between these alternatives.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6644762      PMCID: PMC1049143          DOI: 10.1136/jmg.20.5.330

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  23 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  Antinuclear factor in rapid and slow acetylator patients treated with isoniazid.

Authors:  D A Evans; M F Bullen; J Houston; C A Hopkins; J M Vetters
Journal:  J Med Genet       Date:  1972-03       Impact factor: 6.318

3.  A filter paper method for determining isoniazid acetylator phenotype.

Authors:  W W Weber; W Brenner
Journal:  Am J Hum Genet       Date:  1974-07       Impact factor: 11.025

4.  The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine.

Authors:  A Víznerová; Z Slavíková; G A Ellard
Journal:  Tubercle       Date:  1973-03

5.  The actylation of sulamethazine and sulfamethoxypyridazine by human subjects.

Authors:  T A White; D A Evans
Journal:  Clin Pharmacol Ther       Date:  1968 Jan-Feb       Impact factor: 6.875

6.  Human acetylator polymorphism: estimate of allele frequency in Libya and details of global distribution.

Authors:  A K Karim; M S Elfellah; D A Evans
Journal:  J Med Genet       Date:  1981-10       Impact factor: 6.318

7.  N-acetylation phenotype in bladder cancer.

Authors:  K W Woodhouse; P C Adams; A Clothier; J C Mucklow; M D Rawlins
Journal:  Hum Toxicol       Date:  1982-10

8.  Polymorphic acetylation of nitrazepam.

Authors:  A K Karim; D A Evans
Journal:  J Med Genet       Date:  1976-02       Impact factor: 6.318

9.  Genetic regulation of aromatic amine N-acetylation in inbred mice.

Authors:  I B Glowinski; W W Weber
Journal:  J Biol Chem       Date:  1982-02-10       Impact factor: 5.157

10.  Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.

Authors:  H Schröder; D A Evans
Journal:  Gut       Date:  1972-04       Impact factor: 23.059

View more
  15 in total

1.  What should we do about work related cancer?

Authors:  W R Lee
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-03

Review 2.  Pharmacogenetics and ecogenetics.

Authors:  D P Agarwal; H W Goedde
Journal:  Experientia       Date:  1986-10-15

3.  Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.

Authors:  Y Horai; K Fujita; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Plasma trehalase activity and diabetes mellitus.

Authors:  L C Eze
Journal:  Biochem Genet       Date:  1989-10       Impact factor: 1.890

5.  N-acetylation in healthy and diseased children.

Authors:  E Hadasová; V Brysová; E Kadlcáková
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

7.  Biomonitoring of urinary aromatic amines and arylamine hemoglobin adducts in exposed workers and nonexposed control persons.

Authors:  M Riffelmann; G Müller; W Schmieding; W Popp; K Norpoth
Journal:  Int Arch Occup Environ Health       Date:  1995       Impact factor: 3.015

8.  Acetylation and oxidation phenotypes in malignant lymphoma.

Authors:  P A Philip; H J Rogers; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

10.  Mutagenicity of 4,4'-methylene-bis-(2-chloroaniline) "MOCA" and its N-acetyl derivatives in S. typhimurium.

Authors:  A Hesbert; M C Bottin; J De Ceaurriz
Journal:  Int Arch Occup Environ Health       Date:  1985       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.